Systemic sclerosis, also called scleroderma, is an immune-mediated rheumatic disease that
is characterised by fibrosis of the skin and internal organs and vasculopathy. Although …

Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have …

Lung ailments in rheumatic diseases present unique challenges for diagnosis and
management and are a source of significant morbidity and mortality for patients. Unlike the …

Fibrosis contributes to the development of many diseases and many target molecules are
involved in fibrosis. Currently, the majority of fibrosis treatment strategies are limited to …

Pulmonary fibrosis is associated with a number of specific forms of interstitial lung disease
(ILD) and can lead to progressive decline in lung function, poor quality of life, and, ultimately …

Objectives The objective of this study was to report the experience with rituximab treatment
in a case series of patients with long-standing systemic sclerosis–associated interstitial lung …

Systemic sclerosis is a rare acquired systemic disease characterised by heterogeneous
evolution and outcome. Each year novel insights into the pathogenesis, diagnosis and …

Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are leading causes
of morbidity and mortality in systemic sclerosis (SSc). As symptoms are often under-reported …

Introduction: Interstitial lung disease (ILD) is a common manifestation of connective tissue
disease (CTD). Although the majority of patients with CTD-ILD are stable or slowly …

ABSTRACT Introduction: Systemic sclerosis (SSc) is a systemic autoimmune disease
characterized by vasculopathy, inflammation and fibrosis. These three main disease …